Categories: CancerNews

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, July 20, 2023 (GLOBE NEWSWIRE) —
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date Number of Shares
Outstanding
Total number of voting rights
Total voting rights,
theoretical
1
Total voting rights,
exercisable2
June 30, 2023 34,875,872 36,620,017 36,597,899

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers. 

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter. 

Contacts

Nanobiotix

Nanobiotix Communications

Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com

Nanobiotix Investor Relations

Craig West
SVP, Investor Relations
+1 (617) 583-0211 
investors@nanobiotix.com
Media Relations 
France – Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com

LifeSci Advisors
 
Ligia Vela-Reid 
+44 (0) 7413825310 
lvela-reid@lifesciadvisors.com

___________________
1
The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

Attachment

Staff

Recent Posts

Zepbound Coupons and Discounts From Duty Free Meds

Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…

1 hour ago

Zepbound Coupons and Discounts From Duty Free Meds

Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…

1 hour ago

Rising From the Ashes: Ivy en Rose MedSpa Reopens in San Francisco, Exemplifying Strength and Community Spirit

Beloved MedSpa Overcomes Devastating Fire and Challenges to Continue Serving the Bay Area SAN FRANCISCO,…

1 hour ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development

MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage…

1 hour ago